Virtu KCG Holdings’s Pacira BioSciences PCRX Stock Holding History

Virtu KCG Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$245K	Sell	5,129 -6,267	-55%	-$291K	0.01%	1923
2017 Q1	$520K	Sell	11,396 -1,895	-14%	-$81.9K	0.01%	1334
2016 Q4	$429K	Buy	+13,291	New	+$444K	0.01%	1677
2016 Q3	–	Sell	-23,875	Closed	-$805K	–	3356
2016 Q2	$805K	Buy	23,875 +15,623	+189%	+$768K	0.02%	927
2016 Q1	$437K	Buy	8,252 +4,399	+114%	+$257K	0.01%	1335
2015 Q4	$296K	Sell	3,853 -1,213	-24%	-$68.7K	0.01%	2170
2015 Q3	$208K	Buy	5,066 +1,750	+53%	+$107K	﹤0.01%	2531
2015 Q2	$235K	Sell	3,316 -2,081	-39%	-$164K	﹤0.01%	2393
2015 Q1	$480K	Buy	+5,397	New	+$548K	0.01%	1411
2013 Q4	–	Sell	-4,308	Closed	-$207K	–	4128
2013 Q3	$207K	Buy	+4,308	New	+$157K	﹤0.01%	3089

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Virtu KCG Holdings's PCRX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Pacira BioSciences (PCRX) stake by 55% in Q2 2017, selling an estimated $291K and leaving 5,129 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #1923.

Virtu KCG Holdings first reported a position in PCRX in Q3 2013 and has held it in 10 quarters since. The position peaked at $805K in Q2 2016. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

Virtu KCG Holdings held 5,129 shares of Pacira BioSciences worth $245K as of Q2 2017.
Virtu KCG Holdings sold 6,267 Pacira BioSciences shares in Q2 2017, an estimated $291K.
Pacira BioSciences made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1923 holding.
Virtu KCG Holdings first reported a position in Pacira BioSciences in Q3 2013 and has held it in 10 quarters since.
Virtu KCG Holdings's Pacira BioSciences position peaked at $805K in Q2 2016.
196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.